FDA grants fast track designation to Wockhardt's novel antibiotic WCK 6777
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient parenteral antimicrobial therapy
The product is expected to be launched in Q3FY25
Developed in consultation with clinicians and patients for an enhanced user experience
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results
A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
Subscribe To Our Newsletter & Stay Updated